| Nov 13 |
Gyre Therapeutics GAAP EPS of $0.01, revenue of $25.49M
|
| Nov 13 |
Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
|
| Oct 22 |
Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis
|
| Oct 1 |
Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference
|
| Aug 9 |
Gyre Therapeutics to Present at Sidoti Virtual Investor Conference
|
| Aug 8 |
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors
|
| Jul 2 |
Gyre Therapeutics Announces China’s NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia
|
| Jun 27 |
Estimating The Intrinsic Value Of Gyre Therapeutics, Inc. (NASDAQ:GYRE)
|
| Jun 18 |
Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology
|
| May 30 |
Gyre Therapeutics files to sell 1.08M shares of common stock for holders
|
